AbstractThe clinical understanding and treatment of chronic lymphocytic leukemia (CLL), the most prevalent adult leukemia in the West, has experienced several advances over the past decade. Research on genetic aspects of CLL has expanded medical understanding of its risk stratification, uncovered a new precursor condition – high-count monoclonal B-cell lymphocytosis (MBL) and overall elicited a sizable transformation of CLL’s treatment framework. Traditional chemotherapy-based regimens, which cause severe adverse effects in the elderly and in patients with comorbidities, are now being paired with (and in some cases supplanted by) targeted therapies such as the recently developed monoclonal antibody immunotherapy drugs ofatumumab and obinutuzumab and the targeted kinase inhibitors idelalisib and ibrutinib. These drugs are not only filling a major unmet need of those with newly diagnosed or resistant CLL, but also may reduce or even potentially eliminate the need for chemotherapy. Indeed, the American Society of Clinical Oncology (ASCO) named these new therapy options for CLL the Cancer Advance of the Year in its Clinical Cancer Advances 2015 report.
This article focuses primarily on recent advances in the clinical understanding and treatment of CLL and prognostic implications for insurers.
BackgroundChronic lymphocytic leukemia (CLL) is a slow-developing cancer that is characterized clinically by the overproduction and accumulation of small mature-appearing (but functionally incompetent) B lymphocytes in blood, bone marrow and lymphoid tissues.¹
CLL is the most common adult leukemia in Western societies, with an incidence of 4.2:100,000/year. However, it is relatively rare in Asia3 and Africa. The reason for this geographical diversity is not clear, but the etiopathogenesis is suspected to be more likely due to genetic than environmental factors.4
The risk of developing CLL increases progressively with age. Nearly 70% of patients are 65 years of age or older, and its risk is 2.8 times higher for men than for women.² Read More +
CLL was once thought to be a homogenous static disease, in which B lymphocytes accumulated largely due to lack of normal cell death. Recent research, however, has established CLL as a heterogeneous disease exhibiting constant turnover of malignant B lymphocytes at varying rates. This heterogeneity translates into varying clinical courses and responses to treatment.5,6
More than 80% of CLL patients are diagnosed incidentally. Ten percent of CLL patients present with the characteristic symptoms of fever and night sweats, and approximately 20% to 50% present with enlarged and palpable lymph nodes, hepatomegaly and splenomegaly. A small percentage also experience unexplained weight loss and frequent infections.
Diagnostic criteria for CLL developed by the National Cancer Institute’s Working Group19,25 includes the following:
- A peripheral blood B lymphocyte count of at least 5 × 109/l (5,000/ul)
- Clonality of the circulating B lymphocytes should be confirmed by flow cytometry
- The presence of atypical lymphocytes, cleaved cells or prolymphocytes should not exceed 55% of peripheral lymphocytes
- The lymphocytes should be monoclonal B lymphocytes, expressing B lymphocyte surface antigens CD19, CD20, and CD23 with low surface immunoglobulin and the T cell antigen CD5
- Each clone of leukemia cells is restricted to expression of either kappa or lambda immunoglobulin light chains
Small lymphocytic lymphoma (SLL) is considered the same as CLL by the 2008 World Health Organization (WHO) classification of hematological malignancies due to their identical immunophenotypes. A confirmed diagnosis of SLL requires the presence of lymphadenopathy and/or splenomegaly, and an absolute lymphocyte count in the peripheral blood of less than 5 × 109/l.26
Monoclonal B-cell lymphocytosis (MBL), which today is recognized as a precursor condition to CLL, was first described in 2005.27 MBL is currently defined as the presence of fewer than 5,000 monoclonal B lymphocytes/μl in the blood in the absence of lymphadenopathy, organomegaly, or cytopenia. Based on the size of the clone, MBL can be segregated into two groups:
• Clinical or high-count MBL with ≥0.5 × 109/l clonal B cells. This is a preleukemic disorder; progression to CLL occurs in 1% to 2% of MBL cases per year.
• Low-count MBL, with <0.5 ×109/l clonal B cells. This is seen in approximately 5% of the general population, especially among individuals older than age 70. It has little or no apparent clinical significance.
Table 1 (below) lists the diagnostic differentiators for CLL, SLL and MBL.
Two clinical staging systems are used to predict CLL median survival rates (Table 2,
below).29,30 In Europe, the Binet staging system is more widely used, whereas in the U.S. the Rai system is more commonly applied.
The expanding role of genetic analysis
Studies of somatic copy number variations in genomes using karyotyping, fluorescence in situ hybridization (FISH) or single nucleotide polymorphism arrays have identified several genomic mutations that impact the diagnosis, progression and treatment of CLL. The most recurrent diagnostic variations are deletions of chromosome 13q (55% of cases), 17p (7%), 11q (6% to 18%); and trisomy 12 (12% to 16%).7,8
These chromosomal aberrations might not be wholly responsible for CLL’s clinical
heterogeneity. Mutations of genes such as IgHV (immunoglobulin heavy chain variable) and the protein coding genes TP53, NOTCH1 and SF3B1 also have implications in prognosis and treatment interventions.9 The mutation status for IgHV19 is generally detected using molecular analysis. About 50% of CLL patients present with unmutated IgHV.20,21 These patients have higher genetic instability and higher risk of gaining unfavorable genetic mutations, resulting in shorter overall survival rates.
FISH analysis is usually performed to detect if the long arm of c hromosome 17p, where the TP53 gene resides, has been deleted.16 Patients with a detectable del(17p) mutation or deleted TP53 have the poorest prognoses, with a median overall survival of two to five years.17,18 An extended FISH analysis can also detect additional cytogenetic abnormalities, such as del(11q) or trisomy 12, both of which may have therapeutic consequences. The formerly poor prognosis of patients with del(11q) has improved with the chemotherapy cocktail FCR (fludarabine, cyclophosphamide and rituximab).19
Clonal evolution refers to the process whereby cancer cells acc umulate genetic and epigenetic changes over time, giving rise to new subclones. In CLL, the heterogeneous nature of the disease likely fuels clonal evolution, which is a key point in its progression, relapse, and chemotherapy resistance:22 Over time, 25% of CLL patients develop a new genetic abnormality in coding or non-coding genes.9Across studies, genetic lesions dominating at relapse have been consistently detected in smaller subclones at earlier stages, suggesting the emergence of fitter subclones together with genetic diversification.23 The most consistent lesions detected in these studies have been preexisting TP53 mutations, resulting in highly genomically complex clones at relapse.16 Chemotherapy exposure has also been shown to result in clonal e volution by inducing de novo mutations conferring major fitness of the related subclones.24
There is currently no evidence that early, risk factor-guided intervention with chemoimmunotherapy can alter the natural course of early-st age CLL.4 “Watch and wait,” therefore, remains the standard first-line care for patients with early-stage asymptomatic CLL.
For active symptomatic CLL, the International Workshop on CLL (IWCLL) has specified the following criteria for treatment:31
- Unintentional weight loss of 10% or more within the previous six months
- Significant fatigue
- Fevers higher than 100.5F (38.0C) for two or more weeks without other evidence of infection
- Night sweats for more than one month without evidence of infection
- Cytopenia not caused by autoimmune phenomena
- Symptoms or complications from lymphadenopathy, splenomegaly or hepatomegaly
- Lymphocyte doubling time (LDT) of less than six months (only in patients with more than 30,000 lymphocytes/l [30 × 109/l])
- Autoimmune anemia and/or thrombocytopenia poorly responsive to conventional
The presence in the genome of del(17p) or of a TP53 mutation without the above mentioned conditions are not indications for treatment.
Whether to administer chemoimmunotherapy depends on patient age (e.g., >65 to 70),
fitness level score of >6 (as measured by the Cumulative Illness Rating Scale [CIRS]) and renal function (e.g., creatinine clearance <30 to 50 ml/min).32 Front-line treatment of CLL is based mainly on the stage and the specific genetic mutation expressed.
For fit patients (no comorbidities) without the TP53 mutation, the frontline standard of care is chemoimmunotherapy – specifically FCR. This is based on high response rates (40% to 50% complete response), prolongation of median progression-free survival (PFS) and median overall survival compared with administration of fludarabine and cyclophosphamide or of chlorambucil alone.33,34,35.36
FCR has its own challenges, as it is associated with significant myelosuppression and infections, making it unsuitable for elderly patients and for patients with comorbidities. For older patients with comorbidities and without the TP53 mutation, regimens can include reducedintensity FCR, chlorambucil + CD20 monoclonal antibody (rituximab, obinutuzumab, or ofatumumab), or bendamustine + CD20 monoclonal antibody.
For patients with the TP53 mutation, prognosis is generally poor, even after FCR therapy.39 It is therefore recommended that they be treated with the newer inhibitors ibrutinib (which inhibits the enzyme Bruton’s tyrosine kinase [BTK]) and idelalisib (a phosphoinositide 3-kinase inhibitor), along with rituximab, in both frontline and relapse settings. For transplant-fit patients responding to treatment with these inhibitor drugs, allogeneic hematopoietic stem-cell transplantation (HSCT) may also be considered. HSCT is the only modality with documented curative potential in CLL.40
The breakthrough monoclonal antibody immunotherapy drugs obinutuzumab and of atumumab were approved by the U.S. Food and Drug Administration (FDA) in 2013 and 2009, respectively. The combination of obinutuzumab and chlorambucil was more effective than chlorambucil alone or chlorambucil combined with rituximab, and more than doubled the average time to progression (TTP). The combination of ofatumumab and chlorambucil was also been shown to be superior to single-agent chlorambucil, with an average TTP of 22.4 months versus 13.1 months for chlorambucil alone.38
Newest treatments and therapies
• B-cell receptor (BCR) pathway inhibitors
Currently ibrutinib and idelalisib are approved in the U.S. and Europe for treatment of CLL. Ibrutinib irreversibly inactivates BTK, which is essential for BCR signaling, and nuclear factor-kB (NF-kB), one of the proteins that regulates the expression of genes influencing, among other things, B lymphocyte development and cellular proliferation. Ibrutinib is approved for the treatment of CLL patients who have received at least one round of prior therapy and as the primary therapy for CLL patients presenting with chromosome 17p13.1 deletion.41,42
Acalabrutinib, a second-generation selective BTK inhibitor, has shown promising results for relapsed CLL patients and was recently recommended for orphan drug designation in Europe. It has fewer side effects than ibrutinib, and has shown promise regarding safety and efficacy, including for those with chromosome 17p13.1 deletion.44
Idelalisib is a selective and reversible inhibitor of PI3Kδ, the delta isoform of the enzyme phosphorinositide 3-kinase, which regulates cellular growth and proliferation in leukocytes. In combination with rituximab, idelalisib is a safe and effective new treatment option for patients with relapsed CLL, including those with poor prognostic factors. In a study, patients treated with idelalisib and rituximab lived, on average, 10.7 months without the disease progressing, compared with approximately 5.5 months for participants treated with a placebo plus rituximab.45
• B-cell lymphoma-2 (BCL-2) antagonists
BCL-2 is a prosurvival protein which causes apoptosis resistance and accumulation of long-lived clonal lymphocytes in CLL. Venetoclax (ABT-199, RG7601, GDC-0199), a potent BCL-2 inhibitor, has been granted breakthrough designation by FDA for ultra high risk populations with relapsed/refractory del(17p) CLL. A recent study showed that the overall response rate was 79%, the complete response rate 20%, and the 15 month progression-free survival estimate 69%.46
• Chimeric antigen receptors (CARs-T)
Recent clinical studies are investigating the use of chimeric antigen receptor (CAR) modified T cells to treat CLL. CAR-modified T cells have been developed to target antigen CD19 expressed on CLL cells. Treatment of bulky, relapsed, refractory and high-risk CLL with anti-CD19 CAR-modified T cells can result in sustained remissions in small numbers of patients.47
Insurance considerationsCLL is undergoing a rapid and exciting transition right now, from what was, for many, a fatal disease to one that can be controlled for extended periods of time with an array of relatively well-tolerated therapies that to date exhibit very modest long-term risks.
Molecular genetics is changing CLL by offering superior prognostication and treatment strategies. As the understanding of and treatment frameworks for this condition continue to evolve, so are its underwriting risk classifications. Some early-stage favorable cases now exhibit insurable (albeit moderately reduced) life expectancies. Morbidity concerns with CLL, however, still are negatively impacting the ability to consider living benefits coverage.
Promising new therapies for relapsed, refractory and high-risk CLL have shown a remarkable increase in overall survival and progression-free survival, which could impact terminal illness products as the policy terms may no longer be fulfilled.
While developing critical illness products, insurers would be advised to evaluate precursor CLL conditions such as high-count MBL along with early-stage CLL to prevent unanticipated claims, as these conditions may not meet the “serious illness” spirit of the product, given their long life expectancies and the “watch and wait” treatment approach.
Survival in CLL patients over time has improved significantly due to the many new targeted therapies, which are improving not only response rates and progression-free survival, but also overall survival. Additionally, patients who are ineligible for conventional therapies who have relapsed or whose conditions are resistant now have new options, offering the chance of effective treatment. As these trends continue to evolve, insurers will need to watch and track them carefully.
References1. Kipps TK. Chronic Lymphocytic Leukemia and Related Diseases. In Kaushansky K, Lichtman MA, Beutler E et al. Williams Hematology 8th edition. McGraw-Hill 2010. Chapter 94.
2. Diehl LF, Karnell LH, Menck HR. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer. 1999 Dec 15;86(12):2684-92.
3. Monserrat E, Hillmen P. Chronic Lymphocytic Leukemia. From Hoffbrand V (ed), Higgs DR, Keeling DM, Mehta AB. Postgraduate Haematology 7ed, Wiley, Chapter 27.
4. Malhotra, H, Kumar L, Malhotra P, Hiwase D, Bhatia R, Chronic Leukemias. From Kerr DJ, Haller DG et al. (eds.) Oxford Textbook of Oncology 3ed, Oxford University Press, Chapter 52.
5. Guièze R, Wu CJ. Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood. 2015 Jul 23,126(4);445-53.
6. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Wierda WG, O'Brien S, Wang X et al. Blood. 2007 Jun 1;109(11) 4679-85.
7. Döhner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. New England Journal of Medicine. 2000 Dec 28;343(26):1910-6.
8. Brown JR, Hanna M, Tesar B et al. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clinical Cancer Research. 2012 Jul 15;18(14):3791-802.
9. Puiggros A, Blanco G, Espinet B. Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go. BioMed Research International. Vol. 2014, Article ID 435983, 13 pages.
10. Rossi D, Rasi S, Spina V et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013 Feb 21;121(8):1403-12.
11. Tam CS, Shanafelt TD, Wierda WG et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M.D. Anderson and Mayo Clinic experience. Blood. 2009 Jul 30;114(5):957-64.
12. Hernández JA, Rodríguez AE, González M et al. A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. Haematologica. 2009 Mar; 94(3):364-71.
13. van Dyke DL, Shanafelt TD, Call TG et al. A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. The British Journal of Haematology. 2010 Feb;148(4):544-50.
14. Dal Bo M, Rossi FM, Rossi D et al. 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes, Chromosomes and Cancer. 2011 Aug;50(8);633-43.
15. Marasca R, Maffei R, Martinelli S et al. Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. Hematological Oncology. 2013 Jun;31(2):88-95.
16. Baliakas P, Hadzidimitriou A, Sutton LA et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015. Feb; 29(2):329-36.
17. Pflug N, Bahlo J, Shanafelt TD et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014 Jul 3;124(1):49-62.
18. Döhner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000 Dec 28;343(26):1910-6.
19. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute – Working Group 1996 guidelines. Blood. 2008 Jun 15;111(12):5446-56.
20. Damle RN, Wasil T, Fais F et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999 Sep 15;94(6):1840-7.
21. Hamblin TJ, Orchard JA, Ibbotson RE et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002 Feb. 1;99(3):1023-9.
22. Schuh A, Becq J, Humphray S et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood. 2012 Nov. 15;120(20):4191-6.
23. Dreger P, Schetelig J, Andersen N et al. Managing highrisk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood. 2014 Dec 18;124(26):3841-9.
24. Landau DA, Carter SL, Stojanov P et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013 Feb 14;152(4):714-26.
25. Cheson BD, Bennett JM, Grever M et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996 Jun 15;87(12):4990-7.
26. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues 4e. Lyon, France: IARC Press; 2008.
27. Marti GE, Rawstron AC, Ghia P et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. British Journal of Haematology. 2005 Jun 1;130(3):325-32.
28. Delgado J, Santacruz R, Baumann T, Montserrat E. New developments in chronic lymphocytic leukemia diagnosis. European Oncology & Haematology. 2013;9(2):114-8.
29. Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981 Jul 1;48(1):198-206.
30. Rai KR, Sawitsky A, Cronkite EP et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug;46(2):219-34.
31. Schweighofer CD, Cymbalista F, Müller C et al. Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves
Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results of a Randomized German-French Cooperative Phase III Trial. Blood. 2013 May;123(21);3255-62.
32. Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009 Feb;50(2):171-8.
33. Tam CS, O’Brien S, Wierda W et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008 Aug 15;112(4):975-80.
34. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000; 343(24): 1750-7.
35. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19(5):1414-20.
36. Hallek M, Fischer K, Fingerle-Rowson G et al. International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-74.
37. Goede V, Fischer K, Busch R et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101-10.
38. U.S. Food and Drug Administration: FDA Approves Ofatumumab. April 17, 2014. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm393823.htm
Retrieved March 10, 2016.
39. Eichhorst B, Dreyling M, Robak T, Monserrat E, Hallek M. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2011;22 (suppl 6): vi50-vi54.
40. http://www.uptodate.com/contents/overviewof-the-treatment-of-chronic-lymphocyticleukemia?source=search_result&search=cll+treatment&selectedTitle=1~150. Retrieved April 18, 2016.
41. Imbruvica prescribing information. Sunnyvale, CA: Pharmacyclics, May 2015 https://www.janssenmd.com/pdf/imbruvica/PI-Imbruvica.pdf retrieved April 18, 2016.
42. Imbruvica summary of product characteristics. London: European Medicines Agency, October 2014. http://ec.europa.eu/health/documents/communityregister/2014/20141021129815 anx_129815_en.pdf retrieved April 18, 2016.
© 2016, Reinsurance Group of America, Incorporated. All rights reserved. No part of this publication may be reproduced in any form without the prior permission of the publisher. For requests to reproduce in part or entirely, please contact: email@example.com.
RGA has made all reasonable efforts to ensure that the information provided in this publication is accurate at the time of inclusion and accepts no liability for any inaccuracies or omissions. None of the information or opinions contained in this publication should be construed as constituting medical advice.